Lilly raises 2026 revenue guidance to $91–92 billion as third-quarter revenue rises 39%

Revenue reached $24.4 billion; separately, Lilly said retatrutide beat Ozempic's top dose on A1C and weight loss in a head-to-head Phase 3 trial, per company data.